c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis
Takatsune Shimizu(Hoshi University), Hideyuki Saya(Fujita Health University Hospital), Takeshi Miyamoto(Kumamoto Health Science University), Shinji Kuninaka(Keio University), Hideo Morioka, Hitoshi Ichikawa(National Cancer Research Institute), Yumi Matsuzaki(National Cerebral and Cardiovascular Center), Akira Kawai(NTT (Japan)), Eiji Sugihara(Fujita Health University), Seiji Okada(Kumamoto University), Tatsuhiko Tsunoda(University of California San Diego), Fuyuki Miya(Keio University), Toshio Suda(Chinese Academy of Sciences), Yo Mabuchi(Keio University), Robert Nakayama(Keio University), Tadashi Hasegawa(Sapporo Medical University Hospital), Tatsuo Ito(Osaka National Hospital), Y. Toyama(Keio University Hospital), T. Ishikawa(Daiichi Sankyo (Germany)), Y. Ikeda, Eisuke Kobayashi
Cited by 152
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
|Nature Genetics|2009|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899